Ind-Swift Laboratories Limited

Sahastraa Advisors bought 4,75,000 shares of Ind-Swift Laboratories for ₹6.26 Cr at ₹131.74 apiece in a bulk deal on April 17, 2026.

A pharmaceutical manufacturer engaged in the production of bulk drugs and formulations, Ind-Swift Laboratories operates across India's medicinal compounds sector. Established in 1995, the company focuses on developing and supplying active pharmaceutical ingredients and finished dosage forms to both domestic and international markets. Its integrated operations span research, manufacturing, quality control, and distribution within the broader pharmaceutical value chain.

Mumbai-based financial services private limited company incorporated in May 2022 with paid-up capital of Rs 10 crore. Operates a proprietary investment book in Indian listed equities. Disclosed positions typically surface in smallcap and microcap shareholding filings.